Compare Natco Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA STRIDES PHARMA SCIENCE NATCO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 15.6 16.1 97.0% View Chart
P/BV x 3.1 1.0 322.2% View Chart
Dividend Yield % 1.5 0.5 284.6%  

Financials

 NATCO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
NATCO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,0801,147 94.2%   
Low Rs671642 104.6%   
Sales per share (Unadj.) Rs592.1317.2 186.6%  
Earnings per share (Unadj.) Rs188.47.8 2,401.6%  
Cash flow per share (Unadj.) Rs206.325.1 823.5%  
Dividends per share (Unadj.) Rs8.252.00 412.5%  
Dividend yield (eoy) %0.90.2 421.4%  
Book value per share (Unadj.) Rs833.6274.3 304.0%  
Shares outstanding (eoy) m36.9089.50 41.2%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.52.8 52.5%   
Avg P/E ratio x4.6114.0 4.1%  
P/CF ratio (eoy) x4.235.7 11.9%  
Price / Book Value ratio x1.13.3 32.2%  
Dividend payout %4.425.5 17.2%   
Avg Mkt Cap Rs m32,31180,058 40.4%   
No. of employees `0004.82.5 192.7%   
Total wages/salary Rs m3,2564,341 75.0%   
Avg. sales/employee Rs Th4,522.511,325.8 39.9%   
Avg. wages/employee Rs Th674.01,731.4 38.9%   
Avg. net profit/employee Rs Th1,439.0280.1 513.8%   
INCOME DATA
Net Sales Rs m21,84828,394 76.9%  
Other income Rs m404941 43.0%   
Total revenues Rs m22,25229,334 75.9%   
Gross profit Rs m9,2843,965 234.1%  
Depreciation Rs m6621,540 43.0%   
Interest Rs m1541,962 7.8%   
Profit before tax Rs m8,8721,403 632.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,92097 1,973.3%   
Profit after tax Rs m6,952702 990.2%  
Gross profit margin %42.514.0 304.3%  
Effective tax rate %21.66.9 312.1%   
Net profit margin %31.82.5 1,286.8%  
BALANCE SHEET DATA
Current assets Rs m21,30724,836 85.8%   
Current liabilities Rs m5,92018,993 31.2%   
Net working cap to sales %70.420.6 342.2%  
Current ratio x3.61.3 275.2%  
Inventory Days Days7371 103.2%  
Debtors Days Days107113 93.9%  
Net fixed assets Rs m14,98634,289 43.7%   
Share capital Rs m369895 41.2%   
"Free" reserves Rs m30,35323,651 128.3%   
Net worth Rs m30,76024,546 125.3%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m37,15165,437 56.8%  
Interest coverage x58.61.7 3,417.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.4 135.5%   
Return on assets %19.14.1 469.7%  
Return on equity %22.62.9 790.1%  
Return on capital %29.36.9 425.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32215,697 65.8%   
Fx outflow Rs m2,978735 405.0%   
Net fx Rs m7,34314,962 49.1%   
CASH FLOW
From Operations Rs m4,6361,871 247.8%  
From Investments Rs m-11,1555,826 -191.5%  
From Financial Activity Rs m6,509-10,157 -64.1%  
Net Cashflow Rs m-18-2,615 0.7%  

Share Holding

Indian Promoters % 52.0 27.7 187.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 37.8 20.7%  
FIIs % 16.6 8.6 193.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 25.9 100.4%  
Shareholders   25,395 56,241 45.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS